TXNIP Antibody, Biotin conjugated

Code CSB-PA880966LD01HU
Size US$166
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) TXNIP Polyclonal antibody
Uniprot No.
Target Names
TXNIP
Alternative Names
TXNIP; VDUP1; Thioredoxin-interacting protein; Thioredoxin-binding protein 2; Vitamin D3 up-regulated protein 1
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human Thioredoxin-interacting protein (299-381AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
Biotin
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Tested Applications
ELISA
Protocols
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
May act as an oxidative stress mediator by inhibiting thioredoxin activity or by limiting its bioavailability. Interacts with COPS5 and restores COPS5-induced suppression of CDKN1B stability, blocking the COPS5-mediated translocation of CDKN1B from the nucleus to the cytoplasm. Functions as a transcriptional repressor, possibly by acting as a bridge molecule between transcription factors and corepressor complexes, and over-expression will induce G0/G1 cell cycle arrest. Required for the maturation of natural killer cells. Acts as a suppressor of tumor cell growth. Inhibits the proteasomal degradation of DDIT4, and thereby contributes to the inhibition of the mammalian target of rapamycin complex 1 (mTORC1).
Gene References into Functions
  1. Using oxygen-glucose deprivation and reoxygenation (OGD/R) to create a cell model of hepatic I/R injury, we found that the mRNA and protein expression levels of TXNIP were upregulated in HL7702cells exposed to OGD/R. PMID: 29852169
  2. Expression of TXNIP2 isoform, not TXNIP1, is upregulated in leukocytes of patients with acute myocardial infarction. PMID: 30034557
  3. Thioredoxin-interacting protein (TXNIP) is highly induced in retinal vascular endothelial cells under diabetic conditions. Data (including data from studies using knockout mice) suggest that TXNIP in retinal vascular endothelial cells plays role in diabetic retinal angiogenesis via VEGF/VEGFR2 and Akt/mTOR signaling. (VEGFR2 = vascular endothelial growth factor receptor-2) PMID: 29203232
  4. miR-20a could negatively regulate TLR4 and NLRP3 signaling to protect human aortic endothelial cells from inflammatory injuries. PMID: 29653364
  5. Results found the mRNA level of TRX-1 was significantly decreased (p<0.005), while the mRNA levels of TBP-2, COX-2, and TNF-alpha were significantly increased in the placentas in preeclampsia when compared to the normal group. PMID: 29999276
  6. Consistent with its enhanced expression in Laron syndrome, we provide evidence that TXNIP gene expression is negatively regulated by IGF1. PMID: 29339473
  7. TXNIP contributes to the dysregulation of tubular autophagy and mitophagy in diabetic nephropathy through activation of the mTOR signaling pathway. PMID: 27381856
  8. This study thus characterizes ERK-mediated suppression of TXNIP as a presently unreported mechanism by which ap junctions regulate cell behaviors. PMID: 28694028
  9. Results indicate an internal ribosome entry sites (IRESes) within the thioredoxin-interacting protein (TXNIP) protein; 5' untranslated region (5'UTR), and regulatory IRES trans-acting factors. PMID: 29378331
  10. The data of this study suggested that TXNIP blocked autophagic flux and induced alpha-synuclein accumulation through inhibition of ATP13A2. PMID: 28755477
  11. Compared with normal tissues, TXNIP expression was significantly decreased in human breast cancer tissues and canine mammary tumors, along with tumor progression. PMID: 29524408
  12. This finding suggested statistically significant role of interaction of TXNIP and AF1q polymorphisms (TXNIP-rs2236566, TXNIP-rs7211, and AF1q-rs2769605) in schizophrenia susceptibility. PMID: 27510506
  13. summarize the current state of our understanding of TXNIP biology, highlight its role in metabolic regulation and raise critical questions that could help future research to exploit TXNIP as a therapeutic target PMID: 28137209
  14. intracellular TXNIP protein is a critical regulator of activation of the fructose-induced NLRP3 inflammasome PMID: 28326454
  15. This study provides insight into the molecular mechanisms of TXNIP overexpression in liver cancer cell survival and apoptosis and indicated that TXNIP may be a novel promising agent for liver cancer treatment. PMID: 28440491
  16. Study showed that the expression of TXNIP was significantly increased in RNF2 knockdown prostate tumor cells and that TXNIP is an important downstream target of RNF2. PMID: 28029659
  17. Depletion of glycolytic intermediates led to a consistent decrease in TXNIP expression in response to 1,25(OH)2D3, an effect that coincided with the activation of AMPK signaling and a reduction in c-MYC expression. PMID: 28651973
  18. We found no evidence of decreased TXNIP DNA methylation or increased gene expression in metabolic target tissues of offspring exposed to maternal diabetes. Further studies are needed to confirm and understand the paradoxical SAT TXNIP DNA methylation and gene expression changes in O-GDM subjects PMID: 29077742
  19. the association of TXNIP (thioredoxin-interacting protein) with NLRP3 induced by ROS promoted NLRP3 inflammasome activation in senescent HUVEC endothelial cells PMID: 28064010
  20. histone acetylation serves as a key regulator of glucose-induced increase in TXNIP gene expression PMID: 27989964
  21. thioredoxin-interacting protein deficiency alleviates diabetic renal lipid accumulation through regulation of Akt/mTOR pathway PMID: 27497988
  22. High expression of TXNIP indicates a lower pathological grade of meningnioma, and is also associated with longer recurrence-free time. PMID: 28243945
  23. All-trans retinoic acid plays a key role in inhibition of hepatic stellate cell activation via suppressing TXNIP expression, which reduces oxidative stress levels. PMID: 28322443
  24. Study shows that TXNIP expression is down-regulated in new Multiple Sclerosis (MS) patients compared to controls and might be implicated in pathogenesis of the disease. PMID: 28844667
  25. TXNIP Single nucleotide polymorphisms may individually and cumulatively affect CAD risk through a possible mechanism for regulating TXNIP expression and gene-environment interactions. PMID: 27470124
  26. Taken together, our results firstly reveal that TMAO induces inflammation and endothelial dysfunction via activating ROS-TXNIP-NLRP3 inflammasome, suggest a likely mechanism for TMAO-dependent enhancement in atherosclerosis and cardiovascular risks. PMID: 27833015
  27. results suggest that TXNIP is required early in the apoptotic-inducing pathway resulting from r-Moj-DM binding to the alphav integrin subunit PMID: 27567705
  28. Hypoxia suppresses thioredoxin binding protein-2 gene expression, which may ultimately alter placental development. PMID: 27762463
  29. Heme oxygenase rs2071749 polymorphism was positively associated with obesity in Mexicans. PMID: 27274779
  30. These data identify novel Txnip protein interactions. PMID: 27437069
  31. Glucose exerts strong stimulatory effects on activation histone marks while having inhibitory effects on repression marks in the promoter of the TXNIP gene, and this was associated with a marked increase in expression of the proinflammatory gene in kidney. PMID: 26806835
  32. No evidence that SNPS in TXNIP has effect, but the rs4485648 polymorphism of the TrxR2 gene might exert an independent effect on the development of Diabetic retinopathy. PMID: 26763822
  33. An association has been found between the TXNIP gene methylation pattern and type 2 diabetes mellitus in ischemic stroke patients through epigenetic mechanisms, related to sustained hyperglycemia levels with HbA1c >/= 7%. PMID: 26643952
  34. These findings thereby provide new mechanistic insight into the regulation of TXNIP and beta-cell biology and reveal novel links between proinflammatory cytokines, carbohydrate response element binding protein-mediated transcription, and microRNA signaling. PMID: 26858253
  35. The crystal structure of the complex between a phosphorylated PPxY motif of TXNIP and the SH2 domain of Vav2 reveals a conserved recognition mechanism. PMID: 26919541
  36. Activation of the miR-373-TXNIP-HIF1alpha-TWIST signaling axis is correlated with a worse outcome in patients with breast cancer. PMID: 26196741
  37. Metformin down-regulates high-glucose-induced TXNIP transcription by inactivating ChREBP and FOXO1 in endothelial cells, partially through AMP-activated protein kinase activation PMID: 26147751
  38. Foam cell-released 4-hydroxnonenal activates PPARdelta in Vascular endothelial cells, leading to increased TXNIP expression and consequently to senescence. PMID: 25754218
  39. our data support the hypothesis that TXNIP is an effective target for the treatment of breast cancer. PMID: 25812606
  40. Expression of TXNIP was up-regulated in all three NSCLC cell lines. PMID: 25854388
  41. Data identify the metastasis suppressor TXNIP as new target of miR-224/miR-452 that induces feedback inhibition of E2F1 and show that miR-224/452-mediated downregulation of TXNIP is essential for E2F1-induced EMT and invasion PMID: 25341426
  42. HG-induced NADPH oxidase activation is driven by TXNIP which subsequently triggers NALP3 inflammasome activation in podocytes and ultimately led to podocyte injury PMID: 25834832
  43. Suggest that TXNIP plays a critical role in anti-Her-1/Her-2 treatment and may be a potential prognostic marker in breast cancer. PMID: 25605021
  44. The expression of TXNIP was significantly higher in normal-weight type- 2 diabetic patients than in obese ones. PMID: 25726203
  45. The inhibition of TRX by TXNIP is mediated by an intermolecular disulphide interaction resulting from a novel disulphide bond-switching mechanism. This bond dissociates in the presence of high concentrations of reactive oxygen species. PMID: 24389582
  46. The protein expression level of TXNIP was negatively correlated with the level of miR-373 in MCF-7 cells and in breast cancer tissue of various migration and invasion abilities. TXNIP was regulated by miR-373. PMID: 26122224
  47. data suggest that loss of the p53 tumor suppressor cooperates with Mychigh/TXNIPlow-driven metabolic dysregulation to drive the aggressive clinical behavior of TNBC. PMID: 25870263
  48. diabetes was associated with a >30-fold increase in TxnIP gene expression and a 17 % increase in TxnIP protein expression. PMID: 24925443
  49. TXNIP has been discovered to control pancreatic B-cell microRNA expression, B-cell function, and insulin production. [Review] PMID: 24911120
  50. regulatory relationship between mTOR and the MondoA-TXNIP axis that we propose contributes to glucose homeostasis PMID: 25332233

Show More

Hide All

Subcellular Location
Cytoplasm.
Protein Families
Arrestin family
Database Links

HGNC: 16952

OMIM: 606599

KEGG: hsa:10628

STRING: 9606.ENSP00000358323

UniGene: Hs.533977

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*